CO7160109A2 - Formulación de implantes de paliperidona - Google Patents
Formulación de implantes de paliperidonaInfo
- Publication number
- CO7160109A2 CO7160109A2 CO14285846A CO14285846A CO7160109A2 CO 7160109 A2 CO7160109 A2 CO 7160109A2 CO 14285846 A CO14285846 A CO 14285846A CO 14285846 A CO14285846 A CO 14285846A CO 7160109 A2 CO7160109 A2 CO 7160109A2
- Authority
- CO
- Colombia
- Prior art keywords
- acid
- weeks
- drug
- composition
- paliperidone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Una composición de liberación sostenida inyectable por vía intramuscular adecuada para la formación de un implante sólidoin situ en un organismo, que comprende un fármaco que es paliperidona y/o sus sales farmacéuticamente aceptables en cualquier combinación de las mismas, un copolímero biocompatible a base de ácido láctico y ácido glicólico con una relación monomérica entre el ácido láctico y el ácido glicólico en el intervalo de 50:50 y DMSO como disolvente, que se caracteriza porque la composición libera el fármaco con un comienzo inmediato de la acción y de manera continua durante al menos ocho semanas y que se caracteriza porque la composición tiene un perfil farmacocinéticoin vivo adecuado para la administración de la formulación cada ocho semanas o períodos aún más largos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170366.4A EP2529757B1 (en) | 2011-05-31 | 2012-05-31 | Paliperidone implant formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7160109A2 true CO7160109A2 (es) | 2015-01-15 |
Family
ID=47074463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14285846A CO7160109A2 (es) | 2012-05-31 | 2014-12-30 | Formulación de implantes de paliperidona |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP2529757B1 (es) |
| JP (1) | JP6430933B2 (es) |
| KR (1) | KR101892496B1 (es) |
| CN (2) | CN104349792A (es) |
| AU (1) | AU2013269546B2 (es) |
| BR (1) | BR112014029208B1 (es) |
| CA (1) | CA2874702C (es) |
| CL (1) | CL2014003215A1 (es) |
| CO (1) | CO7160109A2 (es) |
| CY (1) | CY1114975T1 (es) |
| DK (1) | DK2529757T3 (es) |
| EA (1) | EA029921B1 (es) |
| ES (1) | ES2456917T3 (es) |
| HR (1) | HRP20140158T1 (es) |
| IL (1) | IL235850A0 (es) |
| IN (1) | IN2014DN10673A (es) |
| MA (1) | MA37661B1 (es) |
| MX (1) | MX365097B (es) |
| MY (1) | MY181549A (es) |
| NZ (1) | NZ703319A (es) |
| PH (1) | PH12014502668B1 (es) |
| PL (1) | PL2529757T3 (es) |
| PT (1) | PT2529757E (es) |
| SG (1) | SG11201407971QA (es) |
| SI (1) | SI2529757T1 (es) |
| SM (1) | SMT201400044B (es) |
| UA (1) | UA115987C2 (es) |
| WO (1) | WO2013178811A1 (es) |
| ZA (1) | ZA201409297B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| PT2394663T (pt) | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| PL2529757T3 (pl) * | 2011-05-31 | 2014-04-30 | Farm Rovi Lab Sa | Formulacja implantu zawierającego paliperydon |
| ES2878112T3 (es) * | 2011-05-31 | 2021-11-18 | Farm Rovi Lab Sa | Formulación de implante de risperidona y/o paliperidona |
| UA118732C2 (uk) * | 2015-04-07 | 2019-02-25 | Янссен Фармасьютикалз, Інк. | Схема введення пропущених доз естерів паліперидону тривалої дії для ін'єкційного застосування |
| CN106038569A (zh) * | 2016-05-26 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种帕利哌酮植入剂及其制备方法 |
| SI3506921T1 (sl) * | 2016-08-31 | 2023-10-30 | Mapi Pharma Ltd. | Depojski sistemi, ki vsebujejo glatiramer acetat |
| JP7337080B2 (ja) * | 2017-10-27 | 2023-09-01 | 嘉奥制薬（石家庄）有限公司 | パリペリドンパルミチン酸エステル徐放性懸濁注射液の投薬レジメン |
| EP3801462A4 (en) | 2018-05-24 | 2022-03-16 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
| MX2020012459A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
| CN116528836A (zh) | 2020-11-30 | 2023-08-01 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
| HRP20240074T1 (hr) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem |
| FI4025187T3 (fi) | 2020-11-30 | 2024-02-13 | Janssen Pharmaceutica Nv | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1660039T3 (en) * | 2003-07-18 | 2017-01-16 | Oakwood Laboratories L L C | PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS |
| MX2007001563A (es) | 2004-08-04 | 2008-03-05 | Johnson & Johnson | Composicion para liberacion sostenida de farmaco que demuestra un patron de liberacion ascendente del orden cero, metodos para la elaboracion de dicha composicion. |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8314110B2 (en) | 2007-04-19 | 2012-11-20 | Youxin Li | Compounds for treating mental disorders, and preparation and uses thereof |
| CA2687979C (en) * | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| EP2178872A1 (en) | 2007-07-27 | 2010-04-28 | Synthon B.V. | Paliperidone derivatives |
| CN101932327A (zh) | 2007-12-19 | 2010-12-29 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
| EP2485712A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
| PT2394663T (pt) * | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| ES2589106T3 (es) * | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| PL2529757T3 (pl) * | 2011-05-31 | 2014-04-30 | Farm Rovi Lab Sa | Formulacja implantu zawierającego paliperydon |
| ES2878112T3 (es) * | 2011-05-31 | 2021-11-18 | Farm Rovi Lab Sa | Formulación de implante de risperidona y/o paliperidona |
-
2012
- 2012-05-31 PL PL12170366T patent/PL2529757T3/pl unknown
- 2012-05-31 PT PT121703664T patent/PT2529757E/pt unknown
- 2012-05-31 DK DK12170366.4T patent/DK2529757T3/en active
- 2012-05-31 ES ES12170366.4T patent/ES2456917T3/es active Active
- 2012-05-31 SI SI201230022T patent/SI2529757T1/sl unknown
- 2012-05-31 EP EP12170366.4A patent/EP2529757B1/en active Active
-
2013
- 2013-05-31 KR KR1020147036778A patent/KR101892496B1/ko active IP Right Grant
- 2013-05-31 CA CA2874702A patent/CA2874702C/en active Active
- 2013-05-31 SG SG11201407971QA patent/SG11201407971QA/en unknown
- 2013-05-31 UA UAA201414185A patent/UA115987C2/uk unknown
- 2013-05-31 MX MX2014014484A patent/MX365097B/es active IP Right Grant
- 2013-05-31 IN IN10673DEN2014 patent/IN2014DN10673A/en unknown
- 2013-05-31 WO PCT/EP2013/061319 patent/WO2013178811A1/en active Application Filing
- 2013-05-31 JP JP2015514532A patent/JP6430933B2/ja active Active
- 2013-05-31 NZ NZ703319A patent/NZ703319A/en unknown
- 2013-05-31 EA EA201401348A patent/EA029921B1/ru unknown
- 2013-05-31 MY MYPI2014703550A patent/MY181549A/en unknown
- 2013-05-31 CN CN201380028041.5A patent/CN104349792A/zh active Pending
- 2013-05-31 AU AU2013269546A patent/AU2013269546B2/en active Active
- 2013-05-31 CN CN201910004281.0A patent/CN109966239A/zh active Pending
- 2013-05-31 BR BR112014029208A patent/BR112014029208B1/pt active IP Right Grant
-
2014
- 2014-02-19 HR HRP20140158AT patent/HRP20140158T1/hr unknown
- 2014-02-26 CY CY20141100156T patent/CY1114975T1/el unknown
- 2014-04-03 SM SM201400044T patent/SMT201400044B/xx unknown
- 2014-11-23 IL IL235850A patent/IL235850A0/en active IP Right Grant
- 2014-11-26 CL CL2014003215A patent/CL2014003215A1/es unknown
- 2014-11-28 PH PH12014502668A patent/PH12014502668B1/en unknown
- 2014-12-16 MA MA37661A patent/MA37661B1/fr unknown
- 2014-12-17 ZA ZA2014/09297A patent/ZA201409297B/en unknown
- 2014-12-30 CO CO14285846A patent/CO7160109A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7160109A2 (es) | Formulación de implantes de paliperidona | |
| CO7160108A2 (es) | Formulación de implantes de risperidona o paliperidona | |
| ECSP19078196A (es) | Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| CY1123370T1 (el) | Σταθερη ενεσιμη φαρμακευτικη συνθεση ανταγωνιστη υποδοχεα νευροκινινης 1 και μεθοδος παρασκευης αυτης | |
| BR112015019546A2 (pt) | implante de distribuição de drogas prolongado | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2023002345A1 (es) | Composiciones y métodos para fabricar microparticulas de proteína. | |
| MX2018002462A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| WO2014134586A3 (en) | Injectable long-acting local anesthetic semi-solid formulations and its compostions | |
| CL2017000664A1 (es) | Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| AR097973A1 (es) | FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| NZ738463A (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
| CY1123933T1 (el) | Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης | |
| WO2014119985A3 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
| TR201906297T4 (tr) | Vida kanalı yerleştirme parçası. | |
| TR201005911A2 (tr) | Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu. | |
| CR11141A (es) | Composiciones farmaceuticas y cosmetologicas con base de extracto de sanguijuelas medicinales y plantas medicinales sinergistas |